Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients
A comparative study of deferasirox and deferoxamine
Keywords:
iron chelators, iron overload, thalassemia, efficacy, safetyAbstract
Introduction: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM) despite advances in chelation therapy. The aim of this study was to compare the effectiveness and safety of deferasirox (DFX) and deferoxamine (DFO) as iron-chelating agents in patients with transfusion-dependent β-thalassemia major.
Methods: This prospective randomized study included 60 patients with transfusion-dependent β-TM during the period from September 2014 to September 2015. Their ages were ≥ 6 years, and they had serum ferritin above 1500 µg/L and were on irregular DFO therapy. Patients had regular packed red cell transfusion in a dose of 10 mL/kg/session. They were randomized to receive DFX (single oral daily dose of 20-40 mg/kg/day) or DFO (20-50 mg/kg/day via subcutaneous infusion over 8-10 hours, 5 days a week). Iron overload was determined by serum ferritin level. The primary endpoint was decrease of serum ferritin level below 1500 μg/L. The secondary endpoint was drug safety.
Results: Both drugs significantly reduced serum ferritin (p < 0.001). At the end of follow-up, there were no significant differences between the two groups in serum ferritin levels (p = 0.673) and in percent reduction of ferritin (p = 0.315). There were no significant differences between the two groups in the total amount of blood transfusion (p = 0.166) and average iron intake (p = 0.227). There were no mortalities or any serious adverse effects, neutropenia, arthropathy, or pulmonary toxicity. Gastrointestinal upset and skin rash occurred more frequently with DFX than with DFO (p = 0.254 and 0.095, respectively).
Conclusion: With appropriate dosing and compliance with drugs, both DFX and DFO are generally well tolerated, safe, and effective in reducing serum ferritin levels in iron-overloaded, regularly-transfused thalassemia major patients. Therefore, oral DFX is recommended for more convenience and adherence to the treatment regimen.
References
Shawky RM, Kamal TM. Thalassemia intermedia: An overview. Egyptian Journal of Medical Human
Genetics. 2012; 13(3): 245-55. doi: 10.1016/j.ejmhg.2012.03.006.
El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, et al. Iron chelation in thalassemia:
combined or monotherapy? The Egyptian experience. Ann Hematol. 2008; 87(7): 545-50. doi:
1007/s00277-008-0471-2. PMID: 18351337.
Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassemia today- prediction, prevention and management. Eur J Haematol. 2008; 80(2): 93-106. doi: 10.1111/j.1600- 0609.2007.01018. PMCID: PMC2253710.
Crisponi G, Remelli M. Iron chelating agents for the treatment of iron overload. Coord Chem Rev. 2008;
(10-11): 1225-40. doi: 10.1016/j.ccr.2007.12.014.
Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, et al. Ineffective erythropoiesis in
beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin
and up-regulation of ferroportin. Blood. 2007; 109(11): 5027-35. doi: 10.1182/blood-2006-09-048868.
PMID: 17299088, PMCID: PMC1885515.
Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, et al. Combined chelation
therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. Eur J Haematol.
; 85(1): 36-42. doi: 10.1111/j.1600-0609.2010.01447. PMID: 20331740.
Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassemia major-related iron overload:
the role of deferiprone. J Blood Med. 2012; 3: 119-29. doi: 10.2147/JBM.S27400. PMID: 23112580,
PMCID: PMC3480237.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in Medically
Treated Patients with Homozygous B-Thalassemia. N Engl J Med. 1994; 331(9): 574-8. doi:
1056/NEJM 199409013310903. PMID: 8047081.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox
(ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006; 107(9): 3455-62.
doi: 10.1182/blood-2005-08-3430. PMID: 16352812.
Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, et al. Relative response of
patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox
(ICL670): a 1-yr prospective study. Eur J Haematol. 2008; 80(2): 168-76. doi: 10.1111/j.1600- 0609.2007.00985. PMID: 18028431, PMCID: PMC2268958.
Jensen PD. Evaluation of iron overload. Br J Haematol. 2004; 124(6): 697-711. doi:10.1111/j.1365-2141.
04838.
Kwiatkowski JL. Real-world use of iron chelators. Hematology Am Soc Hematol Educ Program. 2011;
: 451-8. doi: 10.1182/asheducation-2011.1.451. PMID: 22160073.
Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann NY Acad Sci. 2010; 1202:
-9. doi: 10.1111/j.1749-6632.2010.05544. PMID: 20712765.
Cappellini MD, Porter J, El-Beshlawy A, Li C, Seymour JF, Elalfy M, et al. Tailoring iron chelation by
iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias. Haematologica. 2010; 95(4): 557-66. doi: 10.3324/haematol.2009.014696. PMCID:
PMC2857545.
Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW. Combined iron chelation therapy. Ann
N Y Acad Sci. 2010; 1202: 79-86. doi: 10.1111/j.1749-6632.2010.05591. PMID: 20712777.
Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients:
current strategies and future directions. J Blood Med. 2015; 6: 197-209. doi: 10.2147/JBM.S72463. PMID:
, PMCID: PMC4476479.
Ware HM, Kwiatkowski JL. Optimal Use of Iron Chelators in Pediatric Patients. Clin Adv Hematol Oncol.
; 11(7): 433-41.
Goldberg SL, Giardina PJ, Chirnomas D, Esposito J, Paley C, Vichinsky E. The palatability and tolerability
of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013; 60(9): 1507-12. doi:
1002/pbc.24561. PMID: 23637051.
Porter JB. Practical management of iron overload. Br J Haematol. 2001; 115(2): 239-52. doi:
1046/j.1365-2141.2001.03195. PMID: 11703317.
Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk
factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989; 73(3): 403-9. doi:
1111/j.1365-2141.1989.tb07761. PMID: 2605127.
Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an
oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur
J Haematol. 2009; 82(6): 458-65. doi:10.1111/j.1600-0609.2009.01228. PMID: 19187278, PMCID:
PMC2730551.
Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, et al. Efficacy and safety of
defera¬sirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Br J Haematol. 2009; 147(5): 752-9. doi: 10.1111/j.1365-2141.2009.07908. PMID: 19764988, PMCID:
PMC2779992.
Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator,
in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008; 9(13): 2391-402. doi:
1517/14656566.9.13.2391. PMID: 18710363.
Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with defera- sirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up.
Blood. 2011; 118(4): 884-93. doi: 10.1182/blood-2010-11-316646. PMID: 21628399.
Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox
in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010; 115(12): 2364-71. doi:
1182/blood-2009-04-217455. PMID: 19996412.
Freeman AP, Giles RW, Berdoukas VA, Talley PA, Murray IP. Sustained normalization of cardiac function
by chelation therapy in thalassaemia major. Clin Lab Haematol. 1989; 11(4): 299-307. doi: 10.1111/j.1365- 2257.1989.tb00227. PMID: 2605872.
Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al. Prevention of cardiac disease by
subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985; 312(25): 1600-3. doi:
1056/NEJM198506203122503. PMID: 4000198.
Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes
of death in thalassaemia major. Lancet. 1989; 2(8653): 27-30. doi: 10.1016/S0140-6736(89)90264. PMID:
Chan GC, Chan S, Ho PL, Ha SY. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the
growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalas- semia patients. Hemoglobin. 2009; 33(5): 352-60. doi: 10.3109/03630260903211888. PMID: 19814682.
Orzincolo C, Scutellari PN, Castaldi G. Growth plate injury of the long bones in treated beta-thalassemia.
Skeletal Radiol. 1992; 21(1): 39-44. PMID: 1546335.
Lal A, Porter J, Sweeters N, Ng V, Evans P, Neumayr L, et al. Combined Chelation Therapy with
Deferasirox and Deferoxamine in Thalassemia. Blood Cells Mol Dis. 2013; 50(2): 99-104. doi:
1016/j.bcmd.2012.10.006. PMID: 23151373, PMCID: PMC3592978.
Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev. 2009; 23(Suppl 1):
S3-7. doi: 10.1016/S0268-960X(09)70003-7. PMID: 20116637.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
